Valoctocogene Roxaparvovec clinical trials
Also written BMN 270.
How each study uses Valoctocogene Roxaparvovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 29 Jun 2023 · Roctavian · BLA 125720 (FDA, Purple Book)
- European Union
- 24 Aug 2022 · Roctavian · EMEA/H/C/005830 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses Valoctocogene Roxaparvovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsCompletedPhase 1/2BioMarin PharmaceuticalNCT04684940Written as Valoctocogene roxaparvovec
- Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AActive, not recruitingPhase 3BioMarin PharmaceuticalNCT06224907Written as Valoctocogene roxaparvovec
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedPhase 3BioMarin PharmaceuticalNCT04323098Written as valoctocogene roxaparvovec
- Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedPhase 1/2BioMarin PharmaceuticalNCT03520712Written as Valoctocogene Roxaparvovec
- Gene Therapy Study in Severe Haemophilia A Patients (270-201)CompletedPhase 1/2BioMarin PharmaceuticalNCT02576795Written as valoctocogene roxaparvovec
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)CompletedPhase 3BioMarin PharmaceuticalNCT03370913Written as valoctocogene roxaparvovec
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgCompletedPhase 3BioMarin PharmaceuticalNCT03392974Written as Valoctocogene Roxaparvovec
Codes
What other systems call Valoctocogene Roxaparvovec · ClinicalTrials.gg INT001959
- MeSH (NLM) C000723395Valoctocogene RoxaparvovecOne source ClinicalTrials.gov
- UNII (FDA) 681K1JDI8MVALOCTOCOGENE ROXAPARVOVECConfirmed FDA, Wikidata
- Wikidata Q107391591valoctocogene roxaparvovecConfirmed FDA, Wikidata
- NCI Thesaurus C152819Valoctocogene RoxaparvovecConfirmed FDA, Wikidata
- DrugBank DB15561One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723395 | Valoctocogene Roxaparvovec | One source ClinicalTrials.gov |
| UNII (FDA) | 681K1JDI8M | VALOCTOCOGENE ROXAPARVOVEC | Confirmed FDA, Wikidata |
| Wikidata | Q107391591 | valoctocogene roxaparvovec | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152819 | Valoctocogene Roxaparvovec | Confirmed FDA, Wikidata |
| DrugBank | DB15561 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.